Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2228-2236

  Lauvrak, S U ^a   Munthe, E ^a   Kresse, S H ^a   Stratford, E W ^a   Namlos H M ^a   Meza Zepeda, L A ^a   Myklebost, O ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

biomarkers; functional characterisation; gene expression; osteosarcoma; tumorigenicity

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; GROWTH FACTOR; MESSENGER RNA; MICRORNA; MICRORNA 135B 5P; MICRORNA 46A 5P; PROTEIN S 100; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ACTG2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COL1A2 GENE; COLLAGEN GENE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; IN VIVO STUDY; KYNU GENE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NPPB GENE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; RNA ANALYSIS; RUNX2 GENE; S100 GENE; UPREGULATION;

ANIMALS; BONE NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; RNA, MESSENGER;

EID: 84885900540     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.549     Document Type: Article

References (49)

1. Andolfo I, Liguori L, De Antonellis P, Cusanelli E, Marinaro F, Pistollato F, Garzia L, De Vita G, Petrosino G, Accordi B, Migliorati R, Basso G, Iolascon A, Cinalli G, Zollo M (2012) The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro Oncol 14: 596-612.
2. Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK (2011) Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 6: e26121.
3. Caren H, Djos A, Nethander M, Sjoberg RM, Kogner P, Enstrom C, Nilsson S, Martinsson T (2011) Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 11: 66.
4. Chiba T, Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, Saisho H (2005) Identification and investigation of methylated genes in hepatoma. Eur J Cancer 41: 1185-1194.
5. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103: 7024-7029.
6. Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel- Eibrink MM, Zwaan CM, de Haas V, Creutzig U, Klusmann JH, Krauter J, Heuser M, Ganser A, Reinhardt D, Thiede C (2011) Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: A study of the AML-BFM and DCOG study groups. Leukemia 25: 1704-1710.
7. Dawud RA, Schreiber K, Schomburg D, Adjaye J (2012) Human embryonic stem cells and embryonal carcinoma cells have overlapping and distinct metabolic signatures. PLoS One 7: e39896.
8. Drury R, Verghese ET, Hughes TA (2012) The roles of microRNAs in sarcomas. J Pathol 227: 385-391.
9. Dysvik B, Jonassen I (2001) J-Express: exploring gene expression data using Java. Bioinformatics 17: 369-370.
10. Edfeldt K, Bjorklund P, Akerstrom G, Westin G, Hellman P, Stalberg P (2011) Different gene expression profiles in metastasizing midgut carcinoid tumors. Endocr Relat Cancer 18: 479-489.
11. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O (2012) Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16: 2655-2666.
12. Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M (2009) MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 4: e4998.
13. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674.
14. He C, Xiong J, Xu X, Lu W, Liu L, Xiao D, Wang D (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388: 35-40.
15. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
16. Horton WA (1996) Molecular genetic basis of the human chondrodysplasias. Endocrinol Metab Clin North Am 25: 683-697.
17. Kajita M, Ezura Y, Iwasaki H, Ishida R, Yoshida H, Kodaira M, Suzuki T, Hosoi T, Inoue S, Shiraki M, Orimo H, Emi M (2003) Association of the - 381T/C promoter variation of the brain natriuretic peptide gene with low bone-mineral density and rapid postmenopausal bone loss. J Hum Genet 48: 77-81.
18. Komori T (2010) Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 339: 189-195.
19. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M (2012) microRNAs in cancer management. Lancet Oncol 13: e249-e258.
20. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton- Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012) Integrative analysis reveals relationships of epigenetic alterations in osteosarcoma. PLoS One 7: e48262.
21. Kuijjer ML, Namløs HM, Hauben EI, Machado I, Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PC, Meza-Zepeda LA, Myklebost O, Cleton-Jansen AM (2011) mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. BMC Med Genomics 4: 66.
22. Lin ZY, Chuang WL (2012) Genes responsible for the characteristics of primary cultured invasive phenotype hepatocellular carcinoma cells. Biomed Pharmacother 66: 454-458.
23. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2010) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
24. Lucero C, Vega O, Osorio M, Tapia JC, Antonelli M, Stein GS, van Wijnen AJ, Galindo MA (2013) The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol 228: 714-723.
25. Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482: 347-355.
26. Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF, Soares MB (2011) Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011: 732690.
27. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
28. Marini JC, Forlino A, Cabral WA, Barnes AM, San Antonio JD, Milgrom S, Hyland JC, Ko?rkko? J, Prockop DJ, De Paepe A, Coucke P, Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, Kuslich C, Troendle J, Dalgleish R, Byers PH (2007) Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: Regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28: 209-221.
29. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA (2011) The Role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011: 282745.
30. Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
31. Misawa K, Kanazawa T, Misawa Y, Imai A, Endo S, Hakamada K, Mineta H (2011) Hypermethylation of collagen alpha2 (I) gene (COL1A2) is an independent predictor of survival in head and neck cancer. Cancer Biomark 10: 135-144.
32. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, Llombart-Bosch A, Cleton-Jansen AM (2011) Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest 91: 1195-1205.
33. Mori K, Enokida H, Kagara I, Kawakami K, Chiyomaru T, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M (2009) CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. Int J Oncol 34: 1593-1602.
34. Munding JB, Adai AT, Maghnouj A, Urbanik A, Zollner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, Tannapfel A, Hahn SA (2012) Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 131: E86-E95.
35. Namløs HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer M, Serra M, Bu?rger H, Cleton-Jansen AM, Myklebost O (2012) Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One 7: e48086.
36. O?Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D (2008) Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205: 585-594.
37. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort. Genes Chromosomes Cancer 49: 40-51.
38. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
39. PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ (2011) Molecular alterations as target for therapy in metastatic osteosarcoma: A review of literature. Clin Exp Metastasis 28: 493-503.
40. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-599.
41. Schaap-Oziemlak AM, Raymakers RA, Bergevoet SM, Gilissen C, Jansen BJ, Adema G, Ko?gler G, le Sage C, Agami R, van der Reijden BA, Jansen JH (2010) MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev 19: 877-885.
42. Sengupta PK, Smith EM, Kim K, Murnane MJ, Smith BD (2003) DNA hypermethylation near the transcription start site of collagen alpha2(I) gene occurs in both cancer cell lines and primary colorectal cancers. Cancer Res 63: 1789-1797.
43. Skårn M, Namløs HM, Noordhuis P, Wang MY, Meza-Zepeda LA, Myklebost O (2012) Adipocyte differentiation of human bone marrow-derived stromal cells is modulated by microRNA-155, microRNA-221, and microRNA-222. Stem Cells Dev 21: 873-883.
44. Suda M, Ogawa Y, Tanaka K, Tamura N, Yasoda A, Takigawa T, Uehira M, Nishimoto H, Itoh H, Saito Y, Shiota K, Nakao K (1998) Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Proc Natl Acad Sci USA 95: 2337-2342.
45. van den Berg H, Kroon HM, Slaar A, Hogendoorn P (2008) Incidence of biopsy-proven bone tumors in children: A report based on the Dutch pathology registration ?PALGA?. J Pediatr Orthop 28: 29-35.
46. Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, Han J (2011) Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol 26: 1630-1637.
47. Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308.
48. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, Bader AG (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70: 5923-5930.
49. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH, Cai JP (2012) Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett 4: 339-345